Alvotech stock rose 6.2% in pre-open trading after the company resubmitted Biologics License Applications to the U.S. Food and Drug Administration for two of its principal biosimilar programs.
The company filed updated BLAs for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2mg. Those resubmissions follow Alvotech’s response to the FDA’s Post-Application Action Letter regarding its Reykjavik manufacturing facility and are intended to address observations that emerged during a routine current Good Manufacturing Practice surveillance inspection completed in May 2026.
In a statement accompanying the filings, CEO Lisa Graver described the resubmissions as a pivotal development, saying that "these resubmissions represent an important milestone following extensive work across our manufacturing and quality organization." The company has said it expects the FDA to run a six-month review clock on the updated applications.
Commercialization of both products in the U.S. is arranged through a partnership with Teva Pharmaceutical Industries. Alvotech also indicated it is accelerating U.S. launches tied to recent regulatory progress and expects to have five products on the U.S. market by year-end.
Market positioning and analyst view
Before today’s move, Alvotech shares had been under sustained selling pressure and had recently reached a 52-week low. The consensus analyst rating on ALVO is "Buy," with an average price target of $13.83. That consensus implies significant upside from prevailing trading levels and reflects that the market had been pricing in meaningful execution risk for the company.
Alvotech is also expanding manufacturing capacity through a partnership with Fujifilm, a development the company says supports a robust product pipeline. Management has articulated first-to-market ambitions for other high-priority biosimilars in its pipeline, including ENTYVIO and a high-dose Eylea product.
Context in broader markets
Today’s pre-market gain for Alvotech is notable because U.S. equity benchmarks were broadly lower. The S&P 500 was down 2.6%, the Dow Jones Industrial Average was down 1.4%, and the NASDAQ was off 4.2% at the time of reporting. Market data in the session showed Teva trading lower by roughly 0.7%.
The combination of a concrete regulatory catalyst, a deeply discounted valuation relative to analyst targets, and a commercial framework with Teva converged to underpin the pre-market strength in Alvotech shares. With the FDA review clock now running, investors appear to be assigning a meaningful probability to approval within the coming six months, as reflected in intraday price action.
What to watch next
- Progress and correspondence with the FDA during the six-month review period on AVT05 and AVT06.
- Operational updates tied to manufacturing enhancements at the Reykjavik facility and any further observations from regulatory inspectors.
- Commercial rollout milestones with Teva as Alvotech aims to place five products on the U.S. market by year-end.